Thomas Meyer

List of Publications by Year
in descending order

49 papers	3,185 citations	236925 25 h-index	168389 53 g-index
57 all docs	57 docs citations	57 times ranked	4942 citing authors

#	Article	IF	Citations
1	Caregiversâ€™ divergent perspectives on patientsâ€™ well-being and attitudes towards hastened death in Germany, Poland and Sweden. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 252-262.	1.7	2
2	Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology, 2022, 79, 121.	9.0	78
3	Pain-Related Coping Behavior in ALS: The Interplay between Maladaptive Coping, the Patientâ€™s Affective State and Pain. Journal of Clinical Medicine, 2022, 11, 944.	2.4	1
4	Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy. Annals of Clinical and Translational Neurology, 2022, 9, 351-362.	3.7	5
5	Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study. Scientific Reports, 2022, 12, .	3.3	2
6	Nonâ€invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany. European Journal of Neurology, 2021, 28, 1160-1171.	3.3	25
7	Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Annals of Clinical and Translational Neurology, 2021, 8, 1049-1063.	3.7	29
8	Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. European Journal of Neurology, 2021, 28, 2582-2595.	3.3	16
9	Characteristics of pain and the burden it causes in patients with amyotrophic lateral sclerosis â€“ a longitudinal study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-8.	1.7	5
10	A Multi-Center Cohort Study on Characteristics of Pain, Its Impact and Pharmacotherapeutic Management in Patients with ALS. Journal of Clinical Medicine, 2021, 10, 4552.	2.4	4
11	Acceptance of Enhanced Robotic Assistance Systems in People With Amyotrophic Lateral Sclerosisâ€“Associated Motor Impairment: Observational Online Study. JMIR Rehabilitation and Assistive Technologies, 2021, 8, e18972.	2.2	7
12	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
13	Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1007-1009.	1.9	36
14	Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 783-785.	1.9	15
15	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
16	Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD). BMC Neurology, 2019, 19, 222.	1.8	34
17	Prognostic factors in ALS: a comparison between Germany and China. Journal of Neurology, 2019, 266, 1516-1525.	3.6	46
18	Experiences with assistive technologies and devices (ATD) in patients with amyotrophic lateral sclerosis (ALS) and their caregivers. Technology and Disability, 2019, 31, 203-215.	0.6	6

#	Article	IF	Citations
19	The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. Journal of Neurology, 2018, 265, 1026-1036.	3.6	29
20	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167
21	Comprehensive analysis of the mutation spectrum in 301 German ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 817-827.	1.9	80
22	Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 342-350.	1.7	33
23	Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications. Journal of Neurology, 2018, 265, 1600-1606.	3.6	34
24	Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study. JMIR Rehabilitation and Assistive Technologies, 2018, 5, e10099.	2.2	26
25	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.7	63
26	Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 53-59.	1.7	26
27	A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 325-336.	1.7	14
28	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
29	Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain, 2016, 139, 1106-1122.	7.6	80
30	Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosisâ€"A Pilot Study. PLoS ONE, 2015, 10, e0139684.	2.5	53
31	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	14.8	652
32	Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial. PLoS ONE, 2014, 9, e97803.	2.5	45
33	Differences in pain perception during open muscle biopsy and Bergstroem needle muscle biopsy. Journal of Pain Research, 2014, 7, 645.	2.0	5
34	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. Neurobiology of Aging, 2014, 35, 2420.e13-2420.e14.	3.1	16
35	Live and let die: existential decision processes in a fatal disease. Journal of Neurology, 2014, 261, 518-525.	3.6	49
36	Severe Loss of Appetite in Amyotrophic Lateral Sclerosis Patients: Online Self-Assessment Study. Interactive Journal of Medical Research, 2013, 2, e8.	1.4	42

#	Article	IF	Citations
37	Online assessment of ALS functional rating scale compares well to in-clinic evaluation: A prospective trial. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 210-216.	2.1	70
38	Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nature Genetics, 2009, 41, 1083-1087.	21.4	344
39	Chemical Hypoxia Facilitates Alternative Splicing of EAAT2 in Presymptomatic APP23 Transgenic Mice. Neurochemical Research, 2008, 33, 1005-1010.	3.3	13
40	Thalidomide causes sinus bradycardia in ALS. Journal of Neurology, 2008, 255, 587-591.	3.6	29
41	Progressive muscle atrophy with hypokalemic periodic paralysis and calcium channel mutation. Muscle and Nerve, 2008, 37, 120-124.	2.2	8
42	Heterozygous S44L missense change of the spastin gene in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 251-253.	2.1	20
43	Breakpoint Cloning and Haplotype Analysis Indicate a Single Origin of the Common Inv(10)(p11.2q21.2) Mutation among Northern Europeans. American Journal of Human Genetics, 2006, 78, 878-883.	6.2	23
44	Early-onset ALS with long-term survival associated with spastin gene mutation. Neurology, 2005, 65, 141-143.	1.1	50
45	Differential regulation of 5â€² splice variants of the glutamate transporter EAAT2 in an in vivo model of chemical hypoxia induced by 3-nitropropionic acid. Journal of Neuroscience Research, 2003, 71, 819-825.	2.9	25
46	High rate of constitutional chromosomal rearrangements in apparently sporadic ALS. Neurology, 2003, 60, 1348-1350.	1.1	18
47	Ifosfamide encephalopathy presenting with asterixis. Journal of the Neurological Sciences, 2002, 199, 85-88.	0.6	23
48	Differential RNA cleavage and polyadenylation of the glutamate transporter EAAT2 in the human brain. Molecular Brain Research, 2000, 80, 244-251.	2.3	21
49	The glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis. Annals of Neurology, 1996, 40, 456-459.	5.3	30